- Home
- IRS vs CVAC Comparison
IRS vs CVAC Comparison
Compare IRS & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRS
- CVAC
- Stock Information
- Founded
- IRS 1943
- CVAC 2000
- Country
- IRS Argentina
- CVAC Germany
- Employees
- IRS N/A
- CVAC N/A
- Industry
- IRS Homebuilding
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- IRS Real Estate
- CVAC Health Care
- Exchange
- IRS Nasdaq
- CVAC Nasdaq
- Market Cap
- IRS 1.1B
- CVAC 1.2B
- IPO Year
- IRS 1994
- CVAC 2020
- Fundamental
- Price
- IRS $15.40
- CVAC $5.48
- Analyst Decision
- IRS
- CVAC Hold
- Analyst Count
- IRS 0
- CVAC 3
- Target Price
- IRS N/A
- CVAC $6.83
- AVG Volume (30 Days)
- IRS 161.5K
- CVAC 771.1K
- Earning Date
- IRS 09-02-2025
- CVAC 08-26-2025
- Dividend Yield
- IRS 6.46%
- CVAC N/A
- EPS Growth
- IRS N/A
- CVAC N/A
- EPS
- IRS 0.20
- CVAC 1.01
- Revenue
- IRS $308,539,877.00
- CVAC $599,540,810.00
- Revenue This Year
- IRS N/A
- CVAC N/A
- Revenue Next Year
- IRS N/A
- CVAC $24.04
- P/E Ratio
- IRS $7.07
- CVAC $5.42
- Revenue Growth
- IRS N/A
- CVAC 675.15
- 52 Week Low
- IRS $9.02
- CVAC $2.37
- 52 Week High
- IRS $17.67
- CVAC $5.72
- Technical
- Relative Strength Index (RSI)
- IRS 50.38
- CVAC 58.75
- Support Level
- IRS $15.48
- CVAC $5.45
- Resistance Level
- IRS $16.83
- CVAC $5.54
- Average True Range (ATR)
- IRS 0.70
- CVAC 0.05
- MACD
- IRS -0.02
- CVAC -0.01
- Stochastic Oscillator
- IRS 37.88
- CVAC 68.42
About IRS IRSA Inversiones Y Representaciones S.A. Global Depositary Shares (Each representing ten shares of)
IRSA Inversiones y Representaciones SA is engaged in a diversified business. The company's operating segment includes Shopping Malls; Offices; Sales and Developments; Hotels and others. It generates maximum revenue from the Shopping Malls segment. The Shopping Malls segment comprised of lease and service revenues related to rental of commercial space and other spaces in the shopping malls of the company.
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.